Why Eli Lilly's Weight-Loss Drug Sales Missed the Mark
Eli Lilly, a company based in Indianapolis, recently faced a blow when its stock prices dipped. The reason? Their weight-loss drugs, Zepbound and Mounjaro, didn't sell as well as expected. The company predicted they'd make about $13. 5 billion in the December quarter, which is less than what experts